RedHill Biopharma Ltd. (RDHL)
5.41
-0.19 (-3.39%)
At close: Jan 14, 2025, 3:58 PM
5.51
1.77%
After-hours Jan 14, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 5.3 |
| Market Cap | 6.90M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -302.63 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 5.7 |
| Volume | 8,745 |
| Avg. Volume (20D) | 16,673 |
| Open | 5.75 |
| Previous Close | 5.60 |
| Day's Range | 5.41 - 5.75 |
| 52-Week Range | 5.41 - 31.50 |
| Beta | undefined |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development pr...
Sector Healthcare
IPO Date Jan 7, 2013
Employees 53
Stock Exchange NASDAQ
Ticker Symbol RDHL
Website https://www.redhillbio.com
4 months ago ·
Source
+25.06%
Redhill Biopharma shares are trading higher after ...
Unlock content with
Pro Subscription
4 months ago ·
Source
+10.76%
Redhill Biopharma shares are trading higher after the company announced results from multiple in vivo studies.
